[en] Since the first treatments against human immunodeficiency virus (HIV) have appeared in 1987, important progress has been accomplished. Twenty-four molecules are currently available but only some of them are in common use on account of their easy administration or their weak adverse effects. Tenofovir disoproxil fumarate (TDF) is a commonly used nucleoside reverse-transcriptase inhibitor (NRTI) of HIV. However, taking TDF is sometimes associated with renal toxicity and increased bone demineralization. Tenofovir alafenamide (TAF) is a new prodrug of tenofovir (TFV) whose security profile is more interesting as far as renal and bone complications are concerned, due to a much lower serum concentration and a high intracellular concentration.
Disciplines :
Immunology & infectious disease
Author, co-author :
SAUVAGE, Anne-Sophie ; Centre Hospitalier Universitaire de Liège - CHU > Service des maladies infectieuses - médecine interne
DARCIS, Gilles ; Centre Hospitalier Universitaire de Liège - CHU > Service des maladies infectieuses - médecine interne
Moutschen, Michel ; Université de Liège - ULiège > Département des sciences cliniques > GIGA-R:Immunopath. - Maladies infect. et médec. inter. gén.
Language :
French
Title :
Actualité thérapeutique dans le VIH: Le ténofovir alafénamide
Alternative titles :
[en] Update in HIV therapy: Tenofovir alafenamide http://www.revmed.ch/contentrevmed/download/181028/1776439
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet 2013;382:1525-33.
Antela A, Aguiar C, Compston J, et al. The role of tenofovir alafenamide in future HIV management. HIV Med 2016;17(Suppl. 2):4-16.
Barelli S, Angelillo-Scherrer A, Kenfak Foguena A, et al. Pathogenèse des maladies cardiovasculaires chez les patients infectés par le VIH: un big bang encore non élucidé ! Rev Med Suisse 2011;7:905-10
UNA IDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. UNAIDS / JC2684. 2014. Available at www.unaids.org/en/resources/documents/2014/90-90-90
Gandhi M, Gandhi RT. Single-pill combination regimens for treatment of HIV-1 infection. N Engl J Med 2014;371:248-59.
Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. Antiviral Res 2016;125:63-70.
Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: The first 4 years. AIDS 2007;21: 1273-81.
Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496-505.
Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother 2007;51:3498-504.
Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008;13:1077-82.
Birkus G, Bam RA, Willkom M, et al. Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors. Antimicrob Agents Chemother 2016;60:316-22.
Sax PE, Wohl D, Yin MT, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: Two randomised, double-blind, phase 3, non-inferiority trials. Lancet 2015;385:2606-15.
Wohl D, Oka S, Clumeck N, et al. Brief Report: A randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results. J Acquir Immune Defic Syndr 2016;72:58-64.
Mills A, Arribas JR, Andrade-Villanueva J, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: A randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. Lancet Infect Dis 2016;16:43-52.
Pozniak A, Arribas JR, Gathe J, et al. Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48-week results from a single-arm, multicenter, open-label phase 3 study. J Acquir Immune Defic Syndr 2016;71:530-7.
Post F, Tebas P, Clarke A, et al. Longerterm safety of tenofovir alafenamide in renal impairment. Boston: CRO I 2016, Feb 22-24.
Kizito H, Gaur A, Prasitsuebsai W, et al. Safety, efficacy and pharmacokinetics of the integrase inhibitor-based E / C / F / TAF single-tablet regimen in treatment-naïve HIV-infected adolescents through 24 weeks of treatment. Seattle: CRO I 2015, Feb 23-26.
Huhn G, Tebas P, Gallant J, et al. Strategic simplification: The efficacy and safety of switching to Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide (E / C / F / TAF ) plus Darunavir (DRV ) in treatment-experienced HIV-1 infected adults (NCT 01968551). ID Week 2015. Oct 9. Oral Abstract Session: Antiretroviral Therapy: New Drugs and Treatment Outcomes.
Agarwal K, Fung SK, Nguyen TT, et al. Twenty-eight day safety, antiviral activity, and pharmacokinetics of tenofovir alafenamide for treatment of chronic hepatitis B infection. J Hepatol 2015;62:533-40.
Gallant J, Brunetta J, Crofoot G, et al. Efficacy and safety of switching to singletablet regimen of Elvitegravir / Cobicistat / Emtricitabine / Tenofovir Alafenamide (E / C / F / TAF ) in HIV-1 / hepatitis B coinfected adults in North America and Japan (NCT 02071082): Week 48 Results. Vancouver: IAS 2015, July 19-23.
